Treatment with rosiglitazone showed a tendency toward decrease in SDF-1 levels (Figure 3 D), but this effect did not reach statistical significance ( p = 0.06 in control PACs and p = 0.12 in db/db PACs).
← all excerpts
PPARγ activation but not PPARγ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.
1
0.0600
0.0600